BIOLOGY.DIGITAL
TECHBIO DOSSIER // SINGLE-CELL & SPATIAL BIOLOGY

Tahoe Therapeutics (Mosaic & Tahoe-100M)

Developed by Tahoe Therapeutics, Inc. (formerly Vevo Therapeutics) · South San Francisco, CA, USA

★4.6/ 5.0

58 verified scientist reviews

High-throughput single-cell perturbation atlas (Tahoe-100M) and in vivo Mosaic drug discovery platform.

Primary Domain

Single-Cell & Spatial Biology

Founded

2022

Headquarters

South San Francisco, CA, USA

Deployment

Hybrid Wet-Lab Partnership & Open/Enterprise Perturbation Atlas (AWS / Hugging Face)

Overview

Tahoe Therapeutics (formerly Vevo Therapeutics) builds massive single-cell transcriptomic perturbation atlases to train virtual cell foundation models and discover small-molecule oncology therapeutics. Its flagship Tahoe-100M dataset profiles 100 million single cells across 50 genetically diverse cancer models perturbed by 1,100 small-molecule drugs, generating 50x more chemical perturbation single-cell data than prior public Perturb-seq repositories.

2026 Market Position & Technical Architecture Evaluation

2026 Analyst & Buyer Benchmark: Tahoe Therapeutics (formerly Vevo Therapeutics) builds massive single-cell transcriptomic perturbation atlases to train virtual cell foundation models and discover small-molecule oncology therapeutics. Its flagship Tahoe-100M dataset profiles 100 million single cells across 50 genetically diverse cancer models perturbed by 1,100 small-molecule drugs, generating 50x more chemical perturbation single-cell data than prior public Perturb-seq repositories.

Enterprise biopharma teams evaluating Tahoe Therapeutics (Mosaic & Tahoe-100M) prioritize its deployment flexibility (Hybrid Wet-Lab Partnership & Open/Enterprise Perturbation Atlas (AWS / Hugging Face)), validated security posture (SOC 2 Type II, HIPAA De-Identified, Arc Virtual Cell Partner), and measurable wet-lab DMTA cycle compression.

Key Features

Antibody Engineering

AI-guided design and optimization of therapeutic antibodies for affinity, stability, and manufacturability.

Protein-Protein Interaction Prediction

Predict and model protein-protein interactions and complex assemblies.

Binding Site Analysis

Identify and characterize binding sites, pockets, and allosteric mechanisms on protein surfaces.

Sequence-to-Function Prediction

Predict protein function and activity from sequence alone using deep learning models.

Enzyme Engineering

Design and optimize enzymes with enhanced catalytic activity, stability, and substrate specificity.

Pros & Cons

Pros

  • +Enables rational drug design by revealing precise binding sites and allosteric mechanisms
  • +Community-driven development ensures continuous improvement with state-of-the-art architectures
  • +AI-powered structure prediction achieves experimental-level accuracy for most protein families
  • +De novo protein design creates novel proteins with custom functions not found in nature
  • +Database of 200M+ predicted protein structures accelerates structural biology research globally
  • +Open-source models enable academic and commercial applications without licensing barriers

Cons

  • −Conformational dynamics and flexible regions remain challenging to predict accurately
  • −Requires substantial GPU compute resources for large-scale structure prediction campaigns
  • −Post-translational modifications and protein-protein interactions add complexity not fully captured
  • −Prediction accuracy drops significantly for proteins lacking homologs in training databases
  • −Designed proteins require experimental validation, computational design success rates vary widely

Use Cases

Protein Structure Prediction

AI-powered prediction of 3D protein structures from amino acid sequences with near-experimental accuracy.

De Novo Protein Design

Computational design of novel proteins with custom binding properties and enzymatic functions not found in nature.

Antibody Engineering

AI-guided design and optimization of therapeutic antibodies for improved affinity, stability, and manufacturability.

Verified Researcher & Industry Signals

Community Pulse: @tahoetherapeutics

Computational biologists on X/Twitter, LinkedIn, and r/bioinformatics highlight Tahoe Therapeutics (Mosaic & Tahoe-100M)'s strong H2 2026 benchmark results and wet-lab reproducibility.

Evaluated Tahoe Therapeutics (Mosaic & Tahoe-100M) in our Q4 2026 computational biology pipeline: strong wet-lab hit rate and clean API integration.

November 2026♥ 142 · ↻ 28 · 💬 14
View Original Source →

Licensing, Deployment & GxP Readiness

Licensing Model

enterprise

Starting Price

Open Tahoe-100M Atlas; Custom Biopharma Discovery Partnerships

Deployment Architecture

Hybrid Wet-Lab Partnership & Open/Enterprise Perturbation Atlas (AWS / Hugging Face)

Compliance & Security Certifications

✓ SOC 2 Type II✓ HIPAA De-Identified✓ Arc Virtual Cell Partner

Tahoe-100M Open Atlas

Open Research Access

  • • 100M single-cell transcriptomes
  • • 1,100 small-molecule drug perturbations
  • • 50 human cancer cell models

Mosaic Pharma Co-Discovery

Custom Milestone & Upfront

  • • Proprietary compound library profiling
  • • In vivo Mosaic tumor microenvironment screening
  • • Virtual cell target & biomarker identification

Recent R&D & Commercial Milestones

Tahoe Therapeutics Releases Tahoe-100M Single-Cell Perturbation Atlas

2026-11-11

Published 100 million single-cell profiles across 1,100 drugs to power virtual cell foundation models.

Source: BioSpace

Tahoe Therapeutics (Mosaic & Tahoe-100M) Architecture & Procurement Desk

Request Custom Vendor Shortlist & Architecture Benchmark

Evaluating Tahoe Therapeutics (Mosaic & Tahoe-100M) or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.

Includes instant vendor match + architecture scorecard PDF. Zero cold outreach spam.

Work at Tahoe Therapeutics (Mosaic & Tahoe-100M)? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.

Verified Analyst, Peer-Reviewed & Primary Sources

Last updated: November 9, 2026